
|Videos|April 10, 2017
Immunotherapeutic Agents in Breast Cancer
Author(s)Leisha A. Emens, MD, PhD
This video reviews the latest trials and research on immunotherapeutic agents being tested in breast cancer.
Advertisement
In this video, Leisha A. Emens, MD, PhD, of the Sidney Kimmel Cancer Center, reviews some of the challenges to treating breast cancer patients with an immunotherapeutic approach and highlights the latest trials and research on different immunotherapies being tested in this setting, including PD-1 and PD-L1 blockade in patients with triple-negative breast cancer as well as other subtypes.
Emens gave a presentation on this topic at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
3
What Does an End-of-Life Doula Do for Patients With Cancer?
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5























































